[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100449217":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":68,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":80,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort A",null,"Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene",[13],"Diagnostic Test: Prostate cancer screening",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort B","Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort C","Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black\u002FAfrican ancestry",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DIAGNOSTIC_TEST","Prostate cancer screening","Physical exam (digital rectal exam), prostate-specific antigen (PSA) and PSA derivatives, and multiparametric MRI of the prostate",[9,15,19],[29],{"name":30,"affiliation":5,"role":31},"Keyan Salari, MD, PhD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Olympia Price","CONTACT","857-238-3838","oprice@partners.org",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":10},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-71.05977,42.35843,{"lat":50,"lon":49},{"type":31,"investigatorFullName":30,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Urologic Oncology","100449217","prostate-cancer-genetic-risk-evaluation-and-screening-study-100449217",false,"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study","Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)","PROGRESS","Inclusion Criteria:\n\n* Men 35-74 years old\n* No known diagnosis of prostate cancer\n* Life expectancy \\>10 years\n* Meet cohort A, B, or C criteria\n* Cohort A: Documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a CLIA-certified laboratory (ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53)\n* Cohort B: A strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing\n* Cohort C: Individuals who self-identify as Black American or Black Caribbean with both parents and all four grandparents of Black\u002FAfrican ancestry\n\nExclusion Criteria:\n\n* Prior diagnosis or treatment of prostate cancer\n* Inability to undergo prostate MRI\n* Inability to receive MRI contrast agent","MALE","35 Years","74 Years",{"count":66,"type":67},400,"ESTIMATED","10 Years","OBSERVATIONAL","This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black\u002FAfrican ancestry and evaluate the utility of prostate MRI as a screening tool. The hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with MRI will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.",[72,73,74,75,76,77,78,79],"Prostatic Neoplasm","Prostate Cancer","BRCA2 Mutation","BRCA1 Mutation","ATM Gene Mutation","MMR Mutation","Lynch Syndrome","Genetic Predisposition to Disease",[81,82,83,78,84,85],"BRCA2","BRCA1","Mismatch Repair Deficiency","HOXB13","Family History of Prostate Cancer","2024-10-05",{"date":88,"type":89},"2024-10-09","ACTUAL",{"date":91,"type":89},"2020-02-12",{"date":93,"type":67},"2040-12",{"name":5,"class":6},1]